This has the potential to be very good news for MNKD's Afrezza and acts to highlight Afrezza's safety profile. The danger of Roche's drug along with other similar acting drugs could be the one catalyst that makes diabetics switch in droves and quickly to the soon to be approved Afrezza. And another reason why the FDA "might" act quickly to approve Afrezza.

http://www.nytimes.com/2013/07/11/business/roche-abandons-new-diabetes-drug.html?_r=0